Paratek Pharmaceuticals Reports Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Paratek Pharmaceuticals (PRTK) PT Lowered to $20 at Baird
November 7, 2018 9:04 AM ESTBaird analyst Michael Ulz lowered the price target on Paratek Pharmaceuticals (NASDAQ: PRTK) to $20.00 (from $30.00) while maintaining a Outperform rating.
The analyst commented, "Management reviewed the recent approval of Nuzyra (October) and reiterated a launch in February 2019, with pre-commercial activities on... More
